Abstract
Although R&D is at the core of knowledge-intensive industries like Pharma, outsourcing parts of its activities hold considerable efficiency and effectiveness potentials. That means managers must understand, which R&D activities can be outsourced and which need to stay in-house in order to ensure competitiveness. Nevertheless, systematic approaches for understanding the finer details of the decision-making process on R&D outsourcing are lacking. To address this gap, we present a framework developed in the context of a multinational company, Bayer. The combination of literature studies and the study of the decision process in the pharmaceutical division at Bayer HealthCare allows us to unfold an outsourcing process model—the filter approach—that includes appropriate decision phases and proper tools. The underlying logic of the model is that outsourcing decisions are rather a learning process with different stages than a rational one-off decision.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Adams C, Branter V (2009) Spending on new drug development. Health Econ 19(2):130–141
CMR International (2009) Pharmaceutical R&D factbook. CMR International, New York
Contractor F, Kumar V, Kundu S, Torben P (2010) Reconceptualizing the firm in a world of outsourcing and offshoring: the organizational and geographical relocation of high-value company functions. J Purch Supply Manag 47(8):1417–1433
DataMonitor (2011) Pharmaceutical key trends 2010. Datamonitor, London
David E, Tramontin T, Zemmel R (2009) Pharmaceutical R&D: the road to positive returns. Nat Rev Drug Discov 8:609–610
Evaluate Pharma (2009) World preview 2014. EvaluatePharma, London
Farrell D (2005) Offshoring: value creation through economic change. J Manage Stud 42(3):675–683
Gupta A, Seshasai S, Mukherji S, Ganguly A (2007) Offshoring: the transition from economic drivers toward strategic global partnership and 24 hour knowledge factors. J Electron Commerce Organizations 5(2):1–23
Howells J, Gagliardi D, Mali K (2008) The growth and management of R&D outsourcing: evidence from UK pharmaceuticals. R&D Manage 38(2):205–219
Jahns C, Hartmann E, Bals L (2006) Offshoring: dimensions and diffusion of a new business concept. J Purch Supply Manag 12(4):218–231
Javalgi R, Dixit A, Scherer R (2009) Outsourcing to emerging markets: theoretical perspectives and policy implications. J Int Manag 15:156–168
Masia N (2006) The cost of developing a new drug. In: Bureau of international information programs focus on intellectual property rights. U.S. Department of state publication, Washington
McIvor R (2005) The outsourcing process. Cambridge University Press, Cambridge
Mol MJ (2005) Does being R&D intensive still discourage outsourcing? Evidence from Dutch manufacturing. Res Pol 34(4):571–582
Morgan Stanley Research Europe (2010) Pharmaceuticals: exit research and create value. Morgan Stanley, New York
Piachaud B (2004) Outsourcing R&D in the pharmaceutical industry. Palgrave Macmillan, Basingstoke
Platts K, Probert D, Canez L (2002) Make versus buy decisions: a process incorporating multi-attribute decision-making. Int J Product Econ 77(3):247–257
Probert D (1996) The practical development of a make-or-buy strategy: the issue of process positioning. Integ Manuf Syst 7(2):44–51
Sen AK (2009) Outsourcing of research and development activities: evidence from U.S. BioPharmaceutical Firms. GJBR 3/1:73–82
Tate W, Ellram L, Bals L, Hartmann E (2009) Offshore outsourcing of services: an evolutionary perspective. Int J Product Econ 120(2):512–524
Teece DJ, Pisano GP, Shuen A (1997) Dynamic capabilities and strategic management. Strateg Manage J 18:509–533
Ulset S (1996) R&D outsourcing and contractual governance: an empirical study of commercial R&D projects. J Econ Behav Organ 30(1):63–82
Van de Water H, Van Peet H (2006) A decision support model based on the analytic hierarchy process for the make or buy decision in manufacturing. J Purch Supply Manag 12(5):258–271
Weiss D, Naik P, Weiss R (2009) The ‘big pharma’ dilemma: develop new drugs or promote existing ones? Nat Rev Drug Discov 8:533–534
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag London
About this chapter
Cite this chapter
Bals, L., Kneis, K.C., Lemke, C., Pedersen, T. (2013). Toward a Flexible Breathing Organization: R&D Outsourcing at Bayer . In: Pedersen, T., Bals, L., Ørberg Jensen, P., Larsen, M. (eds) The Offshoring Challenge. Springer, London. https://doi.org/10.1007/978-1-4471-4908-8_12
Download citation
DOI: https://doi.org/10.1007/978-1-4471-4908-8_12
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-4471-4907-1
Online ISBN: 978-1-4471-4908-8
eBook Packages: EngineeringEngineering (R0)